Research programme: Alzheimer's disease diagnostics - Avid Radiopharmaceuticals

Drug Profile

Research programme: Alzheimer's disease diagnostics - Avid Radiopharmaceuticals

Alternative Names: Tau tangle diagnostic program

Latest Information Update: 01 May 2013

Price : $50

At a glance

  • Originator Avid Radiopharmaceuticals; Siemens Medical Solutions
  • Developer Avid Radiopharmaceuticals
  • Class Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 17 Apr 2013 Preclinical development is ongoing the USA
  • 23 Mar 2010 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route) (Bayer/Avid collaboration)
  • 18 Jul 2006 Preclinical trials in Diagnostic imaging in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top